




FIG. 1





FIG. 2



2E.

FIG. 2 (Continued)




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 6 (Continued)





FIG. 7




FIG. 8

8C.

construct	mutations	purpose
mIL-22 (super-22a)	E43H	Affinity maturation
	S45R	
	Q49S	
	Q116W	
	Q128K	
	N68Q	Glycosylation sites
	N97Q	
mIL22R1	N80D N87D T89Q	Glycosylation sites
mIL10Rβ	N49Q N102Q N161Q N199Q	Glycosylation sites

8D.






FIG. 8 (Continued)






11C.

Cell Line	Mutations (nucleos)
LH10	Q116A/K124A/Q128A
LH24 (22-B4)	Q116A/K124D/Q128A
LH27	E43A/Q116A/K124A/Q128A
LH28 (22-B5)	Q48A/Q116A/K124A/Q128A
LH30 (22-B3)	S45E/Q116A/K124A/Q128A
LH41	R55A
LH42 (22-B1)	E117A
LH48 (22-B2)	N46A/E117A

FIG. 11



12C.

Name	Mutations (human)	Corresponding mouse variant
LH36	Q116A/R124A/R128A	LH10
LH60 (h22-B3)	S45E/Q116A/R124A/R128A	LH30 (22-B3)
LH61 (h22-B1)	E117A	LH42 (22-B1)
LH62 (h22-B2)	N46A/E117A	LH48 (22-B2)

FIG. 12





FIG. 13